Loading stock data…
ACRV
$2.17+0.08 (+3.83%)
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acrivon Therapeutics, Inc. in the Healthcare sector is trading at $2.17. The stock is currently 39% below its 52-week high of $3.56, remaining 20.6% above its 200-day moving average. Technical signals show overbought RSI of 73 and bullish MACD crossover, explaining why ACRV maintains its current momentum and trend strength. The Whystock Score of 20/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 73) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.17
Potential Upside
5%
Whystock Fair Value$2.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$76.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.24%
Volume
Today's trading volume
1.13M
Recent News
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with particular attention on results in serous endometrial cancer. The panel discussion followed a late-
Penny Stocks To Watch In January 2026
As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past market trends, continue to offer intriguing possibilities for those willing to explore smaller or newer companies at accessible price points. By focusing on solid financials and growth potential, these stocks can present unique opportunities for investors looking to tap into under-the-radar...
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares
Even if it's not a huge purchase, we think it was good to see that Peter Blume-Jensen, the Co-Founder of Acrivon...
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.